These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 22642766)

  • 1. Variable performance of commercial epidermal growth factor receptor antibodies in detection of basal-like breast cancer.
    Won JR; Gao D; Grant D; Cupples J; Rahemtulla A; Wolber R; Nielsen TO; Gilks CB
    Histopathology; 2012 Sep; 61(3):518-9. PubMed ID: 22642766
    [No Abstract]   [Full Text] [Related]  

  • 2. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
    Hameed O; Chhieng D; Adams AL
    J Clin Oncol; 2008 Mar; 26(9):1571. PubMed ID: 18349417
    [No Abstract]   [Full Text] [Related]  

  • 5. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivary markers: their role in breast cancer detection.
    Chase WR
    J Mich Dent Assoc; 2000 Feb; 82(2):12. PubMed ID: 11323899
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
    Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
    J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.
    Göhring UJ; Ahr A; Scharl A; Weisner V; Neuhaus W; Crombach G; Holt JA
    J Soc Gynecol Investig; 1995; 2(4):653-9. PubMed ID: 9420872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
    Yu KD; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
    [No Abstract]   [Full Text] [Related]  

  • 14. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.
    Srinivasan R; Gillett CE; Barnes DM; Gullick WJ
    Cancer Res; 2000 Mar; 60(6):1483-7. PubMed ID: 10749108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer.
    Tsang JY; Wong KH; Lai MW; Lacambra MD; Ko CW; Chan SK; Lam CC; Yu AM; Tan PH; Tse GM
    J Clin Pathol; 2013 Apr; 66(4):291-6. PubMed ID: 23268325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidermal growth factor receptor as a prognostic factor of breast cancers].
    Tsutsui S
    Nihon Rinsho; 2000 Apr; 58 Suppl():442-7. PubMed ID: 11026031
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?
    Nannini M; Pantaleo MA; Paterini P; Piazzi G; Ceccarelli C; La Rovere S; Maleddu A; Biasco G
    Colorectal Dis; 2011 May; 13(5):542-8. PubMed ID: 20070321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
    Press MF; Hung G; Godolphin W; Slamon DJ
    Cancer Res; 1994 May; 54(10):2771-7. PubMed ID: 7909495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer.
    Schroeder W; Biesterfeld S; Zillessen S; Rath W
    Anticancer Res; 1997; 17(4A):2799-802. PubMed ID: 9252718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?
    Rampaul RS; Pinder SE; Wencyk PM; Nicholson RI; Blamey RW; Robertson JF; Ellis IO
    Clin Cancer Res; 2004 Apr; 10(7):2578. PubMed ID: 15073139
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.